PMID- 20028382
OWN - NLM
STAT- MEDLINE
DCOM- 20100316
LR  - 20181201
IS  - 1349-7006 (Electronic)
IS  - 1347-9032 (Linking)
VI  - 101
IP  - 2
DP  - 2010 Feb
TI  - Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer 
      cells in vitro and inhibits tumor growth in vivo.
PG  - 488-93
LID - 10.1111/j.1349-7006.2009.01415.x [doi]
AB  - Resveratrol, a naturally occurring polyphenolic antioxidant compound present in 
      grapes and red wine, has been reported to hold various biochemical responses. In 
      this preliminary study, we evaluate the chemopreventive potential of resveratrol 
      against bladder cancer and its mechanism of action. Treatment of bladder cancer 
      cells with resveratrol resulted in a significant decrease in cell viability. 
      Resveratrol induced apoptosis through the modulation of Bcl-2 family proteins and 
      activation of caspase 9 and caspase 3 followed by poly(ADP-ribose) polymerase 
      degradation. Treatment with resveratrol led to G(1) phase cell cycle arrest in 
      T24 cells by activation of p21 and downregulation of cyclin D1, cyclin-dependent 
      kinase 4, and phosphorylated Rb. Resveratrol also inhibited the phosphorylation 
      of Akt, whereas the phosphorylation of p38 MAPK was enhanced. In addition, 
      resveratrol treatment decreased the expression of vascular endothelial growth 
      factor and fibroblast growth factor-2, which might contribute to the inhibition 
      of tumor growth on the bladder cancer xenograft model. These findings suggest 
      that reveratrol could be an important chemoprevention agent for bladder cancer.
FAU - Bai, Yu
AU  - Bai Y
AD  - Department of Urology, First Affiliated Hospital, Medical College, Zhejiang 
      University, Hangzhou, China.
FAU - Mao, Qi-Qi
AU  - Mao QQ
FAU - Qin, Jie
AU  - Qin J
FAU - Zheng, Xiang-Yi
AU  - Zheng XY
FAU - Wang, Yun-Bin
AU  - Wang YB
FAU - Yang, Kai
AU  - Yang K
FAU - Shen, Hua-Feng
AU  - Shen HF
FAU - Xie, Li-Ping
AU  - Xie LP
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20091027
PL  - England
TA  - Cancer Sci
JT  - Cancer science
JID - 101168776
RN  - 0 (Anticarcinogenic Agents)
RN  - 0 (Stilbenes)
RN  - EC 2.7.11.24 (p38 Mitogen-Activated Protein Kinases)
RN  - Q369O8926L (Resveratrol)
SB  - IM
MH  - Animals
MH  - Anticarcinogenic Agents/*pharmacology
MH  - Apoptosis/*drug effects
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - G1 Phase/drug effects
MH  - Humans
MH  - Male
MH  - Mice
MH  - Mice, Inbred BALB C
MH  - Resveratrol
MH  - Stilbenes/*pharmacology
MH  - Urinary Bladder Neoplasms/*drug therapy/pathology
MH  - Xenograft Model Antitumor Assays
MH  - p38 Mitogen-Activated Protein Kinases/metabolism
EDAT- 2009/12/24 06:00
MHDA- 2010/03/17 06:00
CRDT- 2009/12/24 06:00
PHST- 2009/12/24 06:00 [entrez]
PHST- 2009/12/24 06:00 [pubmed]
PHST- 2010/03/17 06:00 [medline]
AID - CAS1415 [pii]
AID - 10.1111/j.1349-7006.2009.01415.x [doi]
PST - ppublish
SO  - Cancer Sci. 2010 Feb;101(2):488-93. doi: 10.1111/j.1349-7006.2009.01415.x. Epub 
      2009 Oct 27.